Shionogi & Co., Ltd.

2019/04/22: Notice of Revisions to Dividend Forecasts
2019/04/15: SHIONOGI ANNOUNCES DATA DEMONSTRATING POTENT IN VITRO ACTIVITY OF CEFIDEROCOL AGAINST THE MOST CRITICAL PRIORITY GRAM-NEGATIVE BACTERIAL PATHOGENS
2019/04/12: Acquisition of Marketing Approval for VYVANSE® Capsule 20mg/30mg for Treatment of Attention Deficit Hyperactivity Disorder
2019/04/11: Shionogi Announces Licensing of Symproic® (naldemedine) to BioDelivery Sciences International Inc.
2019/04/11: SHIONOGI Concludes a Contract for the Commercialization of Rizmoic® (naldemedine), an Opioid-Induced Constipation Therapeutic Agent, in Germany, the UK, and the Netherlands
2019/04/04: Shionogi to Present New Data at European Congress of Clinical Microbiology and Infectious Diseases 2019
2019/04/04: SHIONOGI TO PRESENT CLINICAL DATA ON LUSUTROMBOPAG AT THE INTERNATIONAL LIVER CONGRESS™ 2019 OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL)
2019/04/01: SHIONOGI ANNOUNCES SUBMISSION OF CEFIDEROCOL MARKETING AUTHORISATION APPLICATION
2019/04/01: Shionogi Announces the Commencement of its Operations of Shionogi Pharma Co., Ltd.
2019/03/22: Audio Webcasting of the R&D Meeting
2019/03/18: Shionogi to Announce Executive Appointments
2019/03/14: R&D Meeting
2019/03/07: Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets